임욱빈

임욱빈 is a declared insider of 바이오다인 (chief executive), with filings sourced from DART (FSS). The record holds 17 filings, for trades running from 17 March 2021 to 14 August 2026.

Both buying and selling appear: 3 purchases, against 10 sales. The totals exclude 13 filings filed without an amount. Unlike grants, an open-market purchase is paid for by the insider, at the market price. In 2026 alone, the filings show 3 purchases and no sales.

On 14 August 2026 came the latest disclosure, a transaction in 바이오다인. The last insider purchase was made public on 6 July 2026, 125 days ago. Typically, a trade is published a median of 7 days after it takes place. This delay matters because a trade only becomes useful information once it is public. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. These figures are compiled from regulatory filings published by DART (FSS). They describe what insiders did and are not a recommendation.